NCT04194593

Biomarker-based Algorithm for Diagnosis of Glioma

Development of a New Algorithm-based Classification for Glioma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 300 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

ATRX (X-linked mental retardation and alpha-thalassaemia syndrome protein) loss and pTERT (Telomerase reverse transcriptase) mutation are diagnostic markers of gliomas. However, 4 to 28% of gliomas shows none of these alterations. The aim of this project is to propose a new test able to detect the telomeric status for every glioma. Based on this test and other markers (such as mutation of IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2)), investigators propose an algorithm, able to classify the main subtypes of gliomas (astrocytoma, oligodendroglioma and glioblastoma).

Conditions

• Glioma

Interventions

Type	Name	Description
OTHER	PCR (Polymerase Chain Reaction)	Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes). A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm.

Timeline

• Start date: 2018-12-01
• Primary completion: 2020-03-01
• Completion: 2021-03-01
• First posted: 2019-12-11
• Last updated: 2019-12-11

Locations

1 site across 1 country: France